Evidence map›Paper›PMID 30745397›Full record

ArticleAntimicrobial agents and chemotherapy2019

Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model.

Gregory T Robertson, Victoria A Ektnitphong, Michael S Scherman, Matthew B McNeil, Devon Dennison, Aaron Korkegian, Anthony J Smith, Jason Halladay, David S Carter, Yi Xia and 8 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. HowFrontiers in cellular and infection microbiology · 2022
    Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Gregory T RobertsonMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA gregory.robertson@colostate.edu.
Victoria A EktnitphongMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Michael S SchermanMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Matthew B McNeilTB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA.
Devon DennisonTB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA.
Aaron KorkegianTB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA.
Anthony J SmithMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Jason HalladayAnacor Pharmaceuticals, Palo Alto, California, USA.
David S CarterAnacor Pharmaceuticals, Palo Alto, California, USA.
Yi XiaAnacor Pharmaceuticals, Palo Alto, California, USA.
Yasheen ZhouAnacor Pharmaceuticals, Palo Alto, California, USA.
Wai ChoiAnacor Pharmaceuticals, Palo Alto, California, USA.
Pamela W BerryAnacor Pharmaceuticals, Palo Alto, California, USA.
Weimin MaoAnacor Pharmaceuticals, Palo Alto, California, USA.
Vincent HernandezAnacor Pharmaceuticals, Palo Alto, California, USA.
M R K AlleyAnacor Pharmaceuticals, Palo Alto, California, USA.
Tanya ParishTB Discovery Research, Infectious Disease Research Institute, Seattle, Washington, USA.
Anne J LenaertsMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Colorado State University · USInfectious Disease Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

AN12855 is a direct, cofactor-independent inhibitor of InhA in

Indexed as

AnimalsAntitubercular AgentsAza CompoundsBacterial LoadBoron CompoundsDisease Models, AnimalDrug DevelopmentFemaleHydrocarbons, FluorinatedInhibinsIsoniazidLungMiceMice, Inbred C3HMicrobial Sensitivity TestsMycobacterium tuberculosisAN12855Antitubercular AgentsAza CompoundsBoron CompoundsHydrocarbons, Fluorinatedinhibin-alpha subunitInhibinsIsoniazidantimicrobial resistanceC3HeB/FeJ micecaseumdrug developmentisoniazidnecrotic lesionstuberculosis

Identifiers

PMID30745397
PMCPMC6496157
OpenAlexW2911766184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.